- Title Pages
- 1. Introduction
- 2. The nature of migraine: do we need to invoke slow neurochemical processes?
- 3. Contribution of experimental studies to understanding the pathophysiology of migraine
- 4. Genetic epidemiology of migraine
- 5. A possible role of endothelial vasorelaxants in the pathogenesis of migraine
- 6. A classification of peripheral analgesics based upon their mode of action
- 7. Vasomotor functions of trigeminovascular fibres: inferences from lesion studies
- 8. Regional cerebral blood flow in migraine
- 9. Migraine pathogenesis examined with contemporary techniques for analysing brain function
- 10. The superior pericarotid cavernous sinus plexus and cluster headaches
- 11. 5-HT in migraine: evidence from 5-HT receptor antagonists for a neuronal aetiology
- 12. 5-HT in migraine: evidence from 5-HT<sub>1</sub>-like receptor agonists for a vascular aetiology
- 13. Behavioural effects of <i>m</i>-chlorophenylpiperazine (<i>m</i>-CPP), a reported migraine precipitant
- 14. 5-HT receptors and migraine
- 15. Is there still a case for the shunt hypothesis in migraine?
- 16. General discussion I
- 17. Peptidergic mechanisms in human intracranial and extracranial arteries
- 18. Novel agents affecting enkephalinergic and histaminergic transmissions in brain
- 19. The biochemical basis of migraine predisposition
- 20. Depression and migraine
- 21. Pain, headache, and depression: a discussion
- 22. A note on the role of platelets in migraine: a personal view
- 23. Differential abnormalities in signal transduction in migraine and cluster headache
- 24. The current status of migraine therapy
- 25. Treatment: where are we going?
- 26. General discussion II
- 27. The neurovascular basis of migraine: some concluding thoughts
Treatment: where are we going?
Treatment: where are we going?
- (p.294) 25. Treatment: where are we going?
- Migraine: A Spectrum of Ideas
- Oxford University Press
This chapter deals with problems that lie on the borderline between the pathophysiology, the pharmacotherapy, and the pharmacology of migraine. Our hopes must centre on this border, because an intimate and reliable knowledge of these fields will offer a clue towards an optimal therapeutic strategy. Researchers should concentrate on the drugs that have been developed as alternatives to ergotamine. It is to be hoped that these new drugs will be free of the inherent drawback of ergotamine — its deleterious side-effects when given too frequently. Satisfying results in clinical practice could render the prophylactic treatment of migraine superfluous. It could be a real advantage to avoiding prophylactic treatment, which always has to meet the high standards required of any long-term medication.
Oxford Scholarship Online requires a subscription or purchase to access the full text of books within the service. Public users can however freely search the site and view the abstracts and keywords for each book and chapter.
If you think you should have access to this title, please contact your librarian.